Growth of BY-2 Suspension Cells and Plantibody Production in Single-Use Bioreactors

Single-Use Technology in Biopharmaceutical Manufacture

Volumn , Issue , 2011, Pages 251-261

  Raven, Nicole ^a   Schillberg, Stefan ^a   Kirchhoff, Janina ^a   Brändli, Johanna ^b   Imseng, Nicole ^b   Eibl, Regine ^b  

^a FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

^b ZURICH UNIVERSITY OF APPLIED SCIENCES   (Switzerland)

Author keywords

By 2 suspension cells; Cell line; High performance liquid chromatography; Plantibody production; Single use bioreactors

Indexed keywords

EID: 84874795865     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470909997.ch21     Document Type: Chapter

References (63)

1. Wurm FM. (2004). Production of recombinant protein therapeutics in cultivated mammalian cells. Not Biotechnol. 22:1393-1398.
2. Jayapal KR, Wlaschin KF, Hu WS, Yap MGS. (2007). Recombinant protein therapeutics from CHO cells-20 years and counting. Chem. Eng. Prog. 103:40-47.
3. Potgieter Tl, Cukan M, Orummond JE, Houston-Cummings NR, Jiang YW, Li F, Lynaugh H, Mallem M, McKelvey TW, Mitchell T, Nylen A, Rittenhour A, Stadheim TA, Zha DX, d'Anjou M. (2009). Production of monoclonal antibodies by glycoengineered Pichia pastoris. ]. Biotechnol. 139:318-325.
4. Pavlou AK, Reichert JM. (2004). Recombinant protein therapeutics-Success rates, market trends and values to 2010. Nat Biotechnol. 22:1513-1519.
5. Langer ES. (2009). Expression systems royalties battle. BioPhorm International 22(4):37-39.
6. Morrow KJ. (2008). Methods for maximizing antibody yields. Genet. Eng. Biotechnol. News 28:36-40.
7. Jenkins N, Parekh RB, James DC. (1996). Getting the glycosylation right: Implications for the biotechnology industry. Nat. Biotechnol. 14(8):975-981.
8. Gomord V, Sourrouille C, Fitchette AC, Bardor M, Pagny S, Lerouge P, Faye L. (2004). Production and glycosylation of plant-made pharmaceuticals: The antibodies as a challenge. Plant Biotechnol.]. 2:83-100.
9. Jin C, Altmann F, Strasser R, Mach L, Schahs M, Kunert R, RademacherT, Glossl J, Steinkellner H. (2008). A plant-derived human monoclonal antibody induces an anti-carbohydrate immune response in rabbits. Glycobiology 18:235-241.
10. Koprivova A, Stemmer C, Altmann F, Hoffmann A, Kopriva S, Gorr G, Reski R, Decker EL. (2004). Targeted knockouts of Physcomitrella lacking plant-specific immunogenic N-glycans. Plant Biotechnol.]. 2:517-523.
11. Huether CM, Lienhart O, Baur A, Stemmer C, Gorr G, Reski R, Decker EL. (2005). Glyco-engineering of moss lacking plant-specific sugar residues. Plant Biol. (Stuttg.) 7:292-299.
12. Schahs M,Strasser R,Stadlmann J, Kunert R, Rademacher T, Steinkellner H. (2007). Production of a monoclonal antibody in plants with a humanized N-glycosylation pattern. Plant Biotechnol.]. 5:657-663.
13. Strasser R, Stadlmann J, Schahs M, Stiegler G, Quendler H, Mach L, Glossl J, Weterings K, Pabst M, Steinkellner H. (2008). Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotechnol. J. 6:392-402.
14. Twyman RM, Stoger E, Schillberg S, Christou P, Fischer R. (2003). Molecular farming in plants: Host systems and expression technology. Trends Biotechnol. 21:570-578.
15. Doran PM. (2000). Foreign protein production in plant tissue cultures. Curr. Opin. Biotechnol. 11:199-204.
16. Fischer R, LiaoYC, Hoffmann K, Schillberg S, Emans N. (1999). Molecular farming of recombinant antibodies in plants. Biol. Chem. 380:825-839.
17. Fischer R, Twyman RM, Schillberg S. (2003). Production of antibodies in plants and their use for global health. Vaccine 21:820-825.
18. Sijmons PC, Dekker BMM, Schrammeijer B, Verwoerd TC, Vandenelzen PJM, Hoekema A. (1990). Production of correctly processed human serum-albumin in transgenic plants. B/oTechno/ogy 8:217-221.
19. Evans J. (2006). Plant-derived drug approved in US. http:// www.rsc.org/chemistryworld/News/2006/February/07020602. asp. Accessed April 10,2007.
20. Protalix Ltd. (2008). Large scale disposable bioreactor. Patent WO/2008/135991.
21. Protalix Ltd. (2009). Available at htpp://www.protalix.com. Accessed December 1, 2009.
22. Hellwig S, Drossard J, Twyman RM, Fischer R. (2004). Plant cell cultures for the production of recombinant proteins. Not Biotechnol. 22:1415-1422.
23. Nagata T, Nemoto Y, Hasezawa S. (1992). Tobacco BY-2 cell line as the "HeLa" cell in the cell biology of higher plants. Int Rev.Cytol. 132:1-30.
24. Terashima M, Katoh S, Lubon H, Drohan W, Chen L, Beachy R, Stoltz T, Rodriguez RL. (1997). Production of functional human alpha(I)-antitrypsin by rice cell culture. Abstr. Pap. Am. Chem. Soc. 214:18-Agfd.
25. Smith ML, Mason HS, Shuler ML. (2002). Hepatitis B surface antigen (HBsAg) expression in plant cell culture: Kinetics of antigen accumulation in batch culture and its intracellular form. Biotechnol. Bioeng. 80:812-822.
26. Eibl R, Eibl D. (2008). Design of bioreactors suitable for plant cell and tissue cultures. Phytochem. Rev. 7:593-598.
27. Schmale K. (2007). Einsatz von Pflanzenzellkulturen als industriell nutzbare Expressionssysteme für therapeutische Proteine. PhD thesis, RWTH Aachen, Germany.
28. Kieran PM, MacLoughiin PF, Malone DM. (1997). Plant cell Suspension cultures: Some engineering considerations. ]. Biotechnol. 59:39-52.
29. Glicklis R, Mills D, Sitton D, Stortelder W, Merchuk JC. (1998). Polysaccharide production by plant cells in suspension: Experiments and mathematical modelling. Biotechnol. Bioeng. 57:732-740.
30. Doran PM. (2006). Loss of secreted antibody from transgenic plant tissue cultures due to surface adsorption. ]. Biotechnol. 122:39-54.
31. Wongsamuth R, Doran PM. (1994). Foaming and cell flotation in suspended plant cell cultures and the effect of chemical antifoams. Biotechnol. Bioeng. 44:481-488.
32. Shaaltiel Y, Bartfeld D, Hashmueli S, Baum G, Brill-Almon E, Galili G, Dym O, Boldin-Adamsky SA, Silman I, Sussman JL, Futerman A H, Aviezer D. (2007). Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. Plant Biotechnol.]. 5:579-590.
33. Buchs J. (2001). Introduction to advantages and problems of shaken cultures. Biochem. Eng. J. 7:91-98.
34. Raval K, Liu CM, Buchs J. (2006). Large-scale disposable shaking bioreactors. BioProcess Int. 1:46-49.
35. Ducos JP.Terrier B, Courtois D. (2009). Disposable bioreactors for plant micropropagation and cell cultures. In D Eibl, R Eibl (eds.), Disposable Bioreactors, Series: Advances in Biochemical Engineering/Biotechnology, Vol. I 15. Berlin; Heidelberg: Springer, pp. 89-1 15.
36. Girard LS, Fabis M, Bastin M, Courtois D, Pétiard V, Koprowski H. (2006). Expression of a human anti-rabies monoclonal antibody in tobacco cell culture. Biochem. Biophys. Res. Commun. 345:602-607.
37. Huang LF, Liu YK, Lu CA, Hsieh SL, Yu SM. (2005). Production of human serum albumin by sugar starvation induced promoter and rice cell culture. Transgenic Res. 14:569-581.
38. Trexler MM, McDonald KA, Jackman AP. (2002). Bioreactor production of human alpha I -antitrypsin using metabolically regulated plant cell cultures. Biotechnol. Prog. 18:501-508.
39. Huang TK, Plesha MA, Falk BW, Dandekar AM, McDonald KA. (2009). Bioreactor strategies for improving production yield and functionality of a recombinant human protein in transgenic tobacco cell cultures. Biotechnol. Bioeng. 102:508-520.
40. Lee SY, Kim YH. (2002). Stimulation of murine granulocyte macrophage-colony stimulation factor production by Pluronic F-68 and polyethylene glycol in transgenic Nicotiana tabacum cell culture. Biotechnol. Lett. 24:1779-1783.
41. Lee SY, Kim YH, Roh YS, Myoung HJ, Lee KY, Kim Dl. (2004). Bioreactor operation for transgenic Nicotiana tabacum cell cultures and continuous production of recombinant human granulocyte-macrophage colony-stimulating factor by perfusion culture. Enzyme Microb.Technol. 35:663-671
42. Schmale K, Rademacher T. (2006). Towards industrial usefulness-Cryo-cell-banking of transgenic BY-2 cell cultures. J. Biotechno/. 124:302-311.
43. Liu F, Lee JM. (1999). Effect of culture conditions on monoclonal antibody production from genetically modified tobacco suspension cultures. Biotechnol. Bioprocess Eng. 4:259-263.
44. Des Molles DV, Gomord V, Bastin M, Faye L, Courtois D. (1999). Expression of a carrot invertase gene in tobacco suspension cells cultivated in batch and continuous culture conditions./ Biosci. Bioeng. 87:302-306.
45. Mihaliak C, Webb S. (2005). Plant-cell-produced vaccines for animal health. Paper presented at the 2005 International Poultry Scientific Forum, Atlanta, Georgia, January 24-25, 2005.
46. Nechansky A, Schuster M, Jost W, Siegl P, Wiederklum S, Gorr G, Kircheis R. (2007). Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glycol-engineering of therapeutic antibodies. Mol. Immunol. 44:1815-1817.
47. Schuster MJost W, Mudde GC.Wiederkum S, Schwager C, Janzek E, Altmann F, Stadimann J, Stemmer C, Gorr G. (2007). In vivo glyco-engineered antibody with improved lytic potential produced by a non-mammalian expression system. Plant Biotechnol. J. 2:700-708.
48. McDonald KA, Hong LM.Trombly DM, Xie Q, jackman AR (2005). Production of human alpha-l-antitrypsin from transgenic rice cell culture in a membrane bioreactor. Biotechnol. Prog. 21:728-734.
49. Rítala A, Wahlström EH, Holkeri H, Mäkeläinen K, Baez J, Mäkinen K, Nuutila AM. (2008). Production of a recombinant industrial protein using barley cell cultures. Protein Expr. Purif. 59:274-281.
50. An G. (1985). High efficiency transformation of cultured tobacco cells. Plant Physiol. 79:568-570.
51. Sack M, Paetz A, Kunert R, Bomble M, Hesse F, Stiegler G, Fischer R, Katinger H, Stoeger E, Rademacher T. (2007). Functional analysis of the broadly neutralizing human anti-HIV-I antibody 2F5 produced in transgenic BY-2 suspension cultures. FASEB ]. 21:1655-1664.
52. Kay R, Chan A, Daly M, McPherson J. (1987). Duplication of CaMV 35S promoter sequences creates a strong enhancer for plant genes. Science 236:1299-1302.
53. Bevan MW, Flavell RB, Chilton MD. (1992). A chimaeric antibiotic resistance gene as a selectable marker for plant cell transformation. 1983. Biotechnology 24:367-370.
54. Wong C.Waibel R, Sheets M, Mach JP, Finnern R. (2001). Human scFv antibody fragments specific for the epithelial tumour marker MUC-1, selected by phage display on living cells. Cancer Immunol. Immunother. 50:93-101.
55. Kirchhoff J. (2007) Produktion des Muzin-I spezifischen Volllängenantikörpers M12 in Tabaksuspensionszellen. Diploma thesis, Westfälische Wilhelms Universität Münster, Germany.
56. Eibl R, Eibl D, Werner S. (2009). Disposable bioreactors for plant liquid cultures at litre-scale. Eng. Life Sei. 9:156-164.
57. Kreyss E. (2010). Optimierung der Biomasse-und Antikörperproduktion von BY-2 Zellen in geschüttelten, gerührten und wellendurchmischten Kultivierungssystemen. Master thesis, University of Applied Sciences Anhalt, Germany.
58. Sharp JM, Doran PM. (2001). Strategies for enhancing monoclonal antibody accumulation in plant cell and organ cultures. Biotechnol. Prog. 17:979-992.
59. Holland T. (2006). Prozessoptimierung des Expressionsystem Nicotiana tabacum BY-2 zur Produktion des humanen monoklonalen Anti-HIV-Antikörpers 2GI2. Diploma thesis, FH Aachen, Abteilung Jülich, Germany.
60. Diop I. (2008). In vitro Kultivierung einer Antikörper produzierenden Tabaksuspensionszelllinie unter Berücksichtigung verfahrenstechnischer Aspekte in wellendurchmischten Systemen. Bachelor thesis, Zurich University of Applied Sciences, Switzerland.
61. Nieger K. (2008). In vitro Kultivierung einer Antikörper produzierenden Tabaksuspensionszelllinie in gerührten und wellendurchmischten Einweg-Systemen. Bachelor thesis, University of Applied Sciences Anhalt, Germany.
62. Imseng N. (2009). Charakterisierung und Optimierung des Zell wachstums und der Antikörperproduktion einer Tabakzelllinie im CultiFlask-System. Semester thesis, Zurich University of Applied Sciences, Switzerland.
63. Imseng N. (2009). Untersuchung zur Optimierung der Antikörperproduktion der Tabaksuspensionszelllinie MTA. Bachelor thesis, Zurich University of Applied Sciences, Switzerland.